Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Number of lesions with progression and the change in volume of the lesions over 5 years

From: Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study

 SDL group
(n = 26)
Non-SDL group
(n = 34)
P valueTNFi group
(n = 14)
Non-TNFi group
(n = 46)
P value
Erosions, N (%)
 Progression12/51 (23.5)25/60 (41.7)0.0438/26 (30.8)29/85 (34.1)0.751
 Non-progression39/51 (76.5)35/60 (58.3)18/26 (69.2)56/85 (65.9)
Enthesiophytes, N (%)
 Progression17/40 (42.5)33/59 (55.9)0.19015/29 (51.7)36/70 (51.4)0.979
 Non-progression23/40 (57.5)26/59 (44.1)14/29 (48.3)34/70 (48.6)
Mean change of volume
 Erosions (mm3)0.5 ± 1.60.7 ± 1.40.1000.3 ± 1.20.7 ± 1.60.638
 Enthesiophytes (mm3)0.3 ± 0.70.6 ± 0.80.0480.4 ± 0.70.5 ± 0.80.620
  1. Results are mean ± SD or number (percentage). Significant results are highlighted in italics
  2. SDL group achieved sustained DAPSA-LDA, non-SDL group did not achieve sustained DAPSA-LDA, TNFi group patients who received TNF inhibitor throughout 5 years, non-TNFi group patients who did not receive TNF inhibitor throughout 5 years